Difficulty: Medium
Average Score: 80%
Practice
An 83-year-old woman with Parkinson's disease is currently being treated with carbidopa/levodopa, but her Parkinson's symptoms are worsening. She has normal liver function and no history of liver disease. The physician adds tolcapone to her regimen on tolcapone. How does tolcapone help in Parkinson's disease?
Correct answer
B
Rationale
The correct answer is B) Inhibition of COMT.
Rationale:
Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor. COMT is an enzyme that breaks down levodopa outside the blood-brain barrier, reducing the amount of levodopa available to cross into the brain and be converted to dopamine. By inhibiting COMT, tolcapone increases the availability of levodopa in the brain, enhancing its therapeutic effects in Parkinson's disease.
Explanation of other options:
A) Increased norepinephrine synthesis: This is not directly related to the mechanism of action of tolcapone in treating Parkinson's disease. Norepinephrine is not the primary neurotransmitter affected in Parkinson's.
C) Inhibition of MAO: Monoamine oxidase (MAO) inhibitors are a different class of drugs used in depression and anxiety disorders, not Parkinson's disease. MAO inhibitors do not have a direct role in increasing dopamine levels in the brain.
D) Stimulation of acetylcholine release: While acetylcholine does play a role in Parkinson's disease, the primary focus of treatment is on increasing dopamine levels, not acetylcholine release. Stimulation of acetylcholine release would not be the primary mechanism of action for improving Parkinson's symptoms.
Educational context:
Understanding the mechanisms of action of drugs used in Parkinson's disease is crucial for nurses and healthcare professionals caring for patients with this condition. By grasping how medications like tolcapone work, healthcare providers can make informed decisions about treatment options and monitor for potential side effects or interactions. This knowledge enhances patient care and safety in managing Parkinson's disease effectively.
Rationale:
Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor. COMT is an enzyme that breaks down levodopa outside the blood-brain barrier, reducing the amount of levodopa available to cross into the brain and be converted to dopamine. By inhibiting COMT, tolcapone increases the availability of levodopa in the brain, enhancing its therapeutic effects in Parkinson's disease.
Explanation of other options:
A) Increased norepinephrine synthesis: This is not directly related to the mechanism of action of tolcapone in treating Parkinson's disease. Norepinephrine is not the primary neurotransmitter affected in Parkinson's.
C) Inhibition of MAO: Monoamine oxidase (MAO) inhibitors are a different class of drugs used in depression and anxiety disorders, not Parkinson's disease. MAO inhibitors do not have a direct role in increasing dopamine levels in the brain.
D) Stimulation of acetylcholine release: While acetylcholine does play a role in Parkinson's disease, the primary focus of treatment is on increasing dopamine levels, not acetylcholine release. Stimulation of acetylcholine release would not be the primary mechanism of action for improving Parkinson's symptoms.
Educational context:
Understanding the mechanisms of action of drugs used in Parkinson's disease is crucial for nurses and healthcare professionals caring for patients with this condition. By grasping how medications like tolcapone work, healthcare providers can make informed decisions about treatment options and monitor for potential side effects or interactions. This knowledge enhances patient care and safety in managing Parkinson's disease effectively.